Clinical Trials on Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Total 6713 results

Antisoma Research

Unknown

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
PETHEMA Foundation

Completed

Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia (LAMVYX)

Newly Diagnosed Secondary or High Risk AML

Spain
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

Secondary Acute Myeloid Leukemia

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

High-risk (Secondary) Acute Myeloid Leukemia

China
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
University of Michigan Rogel Cancer Center
Genentech, Inc.

Not yet recruiting

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia

United States
Hannover Medical School
University Hospital, Ghent; Johann Wolfgang Goethe University Hospital; University... and other collaborators

Unknown

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

De Novo Akute Myeloid Leukemia (AML) | Secondary Acute Myeloid Leukemia (AML) | Refractory Anemia With Excess of Blasts in Transformation

Germany
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning | Secondary Acute Myeloid Leukemia Evolving From MDS

China
City of Hope Medical Center

Completed

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndromes

United States
Genzyme, a Sanofi Company

Completed

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia (AML)

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Uma Borate
Sumitomo Pharma Oncology, Inc.

Completed

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Acute Myeloid Leukemia | Secondary Myelofibrosis | Acute Myeloid Leukemia in Remission | Primary Myelofibrosis, Prefibrotic Stage

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Secondary Acute Myeloid Leukemia | Alkylating Agent-Related Acute Myeloid Leukemia

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia,...

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States, Canada
Roswell Park Cancer Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia

United States
Bhavana Bhatnagar
CTI BioPharma

Completed

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Adult Acute Myeloid Leukemia... and other conditions

United States
Bhavana Bhatnagar
Karyopharm Therapeutics Inc

Completed

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia-2

China
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With Gene Mutations | FLT3 Tyrosine Kinase Domain Point Mutation

United States
National Cancer Institute (NCI)

Completed

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
Masonic Cancer Center, University of Minnesota
University of Minnesota

Withdrawn

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Treatment-Related Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Seoul National University Hospital

Recruiting

The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder

Korea, Republic of
David Iberri

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults | AML (Adult) With 11q23 (MLL) Abnormalities | AML (Adult) With Del (5q) | AML (Adult) With Inv (16) (p13; q22) | AML (Adult) With t (16;16) (p13; q22) | AML (Adult) With t (8; 21) (q22; q22) and other conditions

United States
National Cancer Institute (NCI)

Terminated

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

Canada
Mendus

Completed

Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) | Leukemic Dendritic Cell Vaccination

Netherlands
European Society for Blood and Marrow Transplantation
Pierre Fabre Medicament

Terminated

Dose-reduced Versus Standard Conditioning in MDS/sAML (RICMAC)

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia

Germany, Italy, Netherlands, Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
St. Jude Children's Research Hospital

Completed

Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies

Lymphoma, Non-Hodgkin | Hodgkin Disease | Chronic Myeloid Leukemia | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Myelodysplastic Syndrome (MDS) | Secondary AML | Juvenile Myelomonocytic Leukemia (JMML) | Secondary MDS

United States
University Hospital, Angers
Saint-Louis Hospital, Paris, France; University Hospital, Brest; Institut Paoli-Calmettes and other collaborators

Not yet recruiting

MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies (MOZART)

Myeloproliferative Neoplasm | Secondary Leukemia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States, Germany
National Cancer Institute (NCI)

Completed

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States

Clinical Trials on Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations